- Lexaria Bioscience Corp (NASDAQ:LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential application against hypertension.
- Related Content: DehydraTECH Delivered Colchicine Can Potentially Treat COVID-19, Side Effects From mRNA Shots.
- At selected times during the 24-hour study, volunteers with mild to moderate hypertension averaged as much as a 20 mmHg (i.e., 23%) decrease in blood pressure (BP) relative to placebo.
- Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 7.0% in systolic pressure with DehydraTECH-CBD relative to placebo.
- Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 5.3% in mean arterial pressure (MAP) with DehydraTECH-CBD relative to placebo.
- Over the 24-hour ambulatory monitoring period, volunteers averaged a significant reduction of 3.5% in diastolic pressure relative to an increase in diastolic pressure (-0.8 vs. +2.7) from baseline with DehydraTECH-CBD relative to placebo.
- Data analysis from the study is continuing, and additional outcomes will be reported upon when complete.
- Read Next: Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months.
- Price Action: LEXX shares are up 15.1% at $7.25 during the premarket session on the last check Tuesday.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!